Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alzai HealthFRA:H2F -1.62%9 EV-to-EBIT is -6.73 as of Aug. 08, 2026. GuruFocus rates FRA:H2F with a GF Score™ of 9/100. The stock has 1 warning sign investors should review. Among 378 Biotechnology companies, Alzai Health ranks worse than 264550% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Alzai Health's Enterprise Value for the quarter that ended in Jan. 2026 was €0.00 Mil.
Alzai Health's EBIT for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alzai Health EV-to-EBIT Related Terms
Alzai Health EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Alzai Health's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alzai Health EV-to-EBIT Chart
Alzai Health Annual Data
Trend
Apr25
EV-to-EBIT
0.00
Alzai Health Quarterly Data
Jan25
Apr25
Jul25
Oct25
Jan26
EV-to-EBIT
0.00
0.00
0.00
0.00
0.00
FRA:H2F vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Alzai Health's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alzai Health EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alzai Health's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Alzai Health's EV-to-EBIT falls into.
Alzai Health's current Enterprise Value is €13.97 Mil.
Alzai Health's EBIT for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alzai Health (FRA:H2F) has a EV-to-EBIT of -6.73 as of Aug. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Alzai Health and its competitors. According to the industry distribution chart, Alzai Health ranks #999999 out of 378 companies in the Biotechnology industry.
Is Alzai Health's EV-to-EBIT too high?
Alzai Health's current EV-to-EBIT is -6.73. Based on the distribution chart, Alzai Health ranks #999999 out of 378 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alzai Health has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Alzai Health's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alzai Health ranks #999999 out of 378 companies for EV-to-EBIT. This places Alzai Health in the lower half of its industry. The industry median EV-to-EBIT is 14.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.03, based on 378 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Alzai Health and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alzai Health's current EV-to-EBIT is -6.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzai Health stock overvalued right now?
Alzai Health (FRA:H2F) has a current EV-to-EBIT of -6.73. The current EV-to-EBIT is -6.73. Alzai Health's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Alzai Health (FRA:H2F), the current EV-to-EBIT is -6.73 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alzai Health Corp is a healthcare company focused on comprehensive health solutions. It is an AI-driven Alzheimer's disease risk screening platform, enabling disease prevention and early disease diagnosis to improve patient outcomes. The company uses low-cost, non-invasive, pre-existing biomarker data present in nearly all Electronic Medical Records of the relevant age demographic. It aims to address the unmet need in Alzheimer's screening, enabling early detection and mitigation driving to diagnosis, therapy or prevention.
9GF Score
Get the complete analysis for FRA:H2F
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:H2F has been successfully added to your 
